March 04, 2005
Vaccine for Prostate Cancer
For the first time, researchers have found that a novel immunologic therapy increases survival by nearly 18 percent in men with advanced prostate cancer that no longer responds to hormone therapy.
The therapeutic cancer vaccine, called APC8015 (Provenge), is likely to become a new standard of care for patients with metastatic prostate cancer. The UCSF-led study is the first to demonstrate a survival benefit from immunologic therapies or vaccines in patients with advanced prostate cancer. (Science Daily)
